Clinical Trials Sector Scorecard 2022: Artificial Intelligence, Virtual Care and Blockchain Saw Activity in Q1 2022 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Clinical Trials Sector Scorecard - Q1 2022 Update - Thematic Research" report has been added to ResearchAndMarkets.com's offering.

Many companies included in the Clinical Trials scorecard have announced partnerships in the artificial intelligence (AI) space since December 2021. Pfizer announced partnerships in drug discovery and disease severity scoring, while Thermo Fisher Scientific announced that it was partnering with Medidata Acorn AI to optimize clinical trials.

Merck KGaA is collaborating with Unlearn.AI to accelerate late-stage trials using AI-based digital twins. In virtual care, Takeda posted several jobs relating to virtual trials and initiated trials with virtual components in Q1 2022, and AstraZeneca, Novo Nordisk, and Otsuka were active in digital health deals. Takeda posted several jobs relating to blockchain in Q1 2022, and Dr. Reddy's is partnering with academia to build a new blockchain solution.

Companies Were Also Active in ESG Initiatives, Driven in Part By the Ukraine Crisis.

While there were no significant changes to Environmental, Social, and Governance (ESG) scores in Q1 2022, several interesting events occurred. Samsung Bioepis released its first annual sustainability report, and in March 2022 Zydus Cadila announced that it was to acquire a stake in AMP Energy Green Nine, a move that is in line with its commitment to enhance its use of renewable power.

AstraZeneca announced that it was developing inhalers that use a more environmentally friendly propellant, HFO-1234ze, and it was also reported that AstraZeneca China employees were being investigated for suspected medical insurance fraud. Many pharma companies have responded to the Ukraine crisis by donating essentials medicines, medical supplies, and financial support to non-governmental organizations (NGOs).

Report Scope:

• The Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trial sector over the next two to four years
• These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain
• The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs)
• It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment
• The methodology section contains information on what data sources were used to generate the thematic scores for each company
• The scorecard is live on the PIC and will be updated quarterly

Key Report Benefits:

• Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market
• Understand which key themes should be addressed to drive share price
• Understand which companies are best positioned for success within critical themes and why
• Learn which companies have underinvested in key themes and are most vulnerable to disruption
• Help companies adapt their strategy to anticipate and benefit from these themes as they play out
• Help identify future winners and losers in drug development to inform partnership strategies

Key Topics Covered:

• Executive Summary
• Pharma Theme Map
• Clinical Trials Scorecard: Key Q1 2022 Updates
• Company Screen
• Thematic Screen
• Valuation Screen
• Thematic Research Methodology
• How the Pharma Scores are Generated

For more information about this report visit https://www.researchandmarkets.com/r/vyil2v

Source: GlobalData

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.